Entrada Tightens Focus on Duchenne Muscular Dystrophy, Axes 20% of Staff

Entrada Therapeutics recently approved a plan to lay off 20% of its workforce as part of a strategic overhaul to focus more intensely on advancing its Duchenne muscular dystrophy (DMD) pipeline1
The FDA lifted a two-year clinical hold on Entrada's DMD therapy ENTR-601-44 in February 2025, allowing the company to proceed with its ELEVATE-44-102 Phase Ib clinical trial in the US23
Entrada plans to begin enrolling patients for its US Phase Ib trial in the first half of 2026, studying ENTR-601-44 in adults with mutations amenable to exon 44 skipping23
The company has already received authorization from UK regulators to begin the ELEVATE-44-102 study, with enrollment expected to begin in Q2 20252
Entrada is also advancing ENTR-601-45, another investigational therapy targeting people with Duchenne who are exon 45 skipping amenable5
The company's strategic focus on underserved DMD subpopulations represents an opportunity in the $3-4 billion global DMD market4
DMD is a rare disease affecting an estimated 41,000 people in the US and Europe, caused by mutations in the DMD gene that lead to inadequate dystrophin production5

Sources:

1. https://firstwordpharma.com/story/5955355

2. https://www.clinicaltrialsarena.com/news/fda-removes-clinical-hold-on-entradas-duchenne-therapy/

3. https://www.fiercebiotech.com/biotech/entradas-2-year-ordeal-ends-fda-lifts-hold-dmd-drug

4. https://www.ainvest.com/news/entrada-therapeutics-pioneering-era-duchenne-muscular-dystrophy-treatment-2504/

5. https://www.globenewswire.com/news-release/2025/03/24/3047704/0/en/Entrada-Therapeutics-Receives-Authorization-in-the-United-Kingdom-to-Initiate-ELEVATE-45-201-a-Phase-1-2-Multiple-Ascending-Dose-Clinical-Study-of-ENTR-601-45-in-People-Living-with.html